A Call To Action: FDA, Social Media and Physician Engagement
Tags: social media, Pharma, FDA, physicians, GI Circle
Joel Selzer (LinkedIn profile), my Co-Founder at Ozmosis, has spent the past few weeks following the buildup to the FDA's Public Hearing on Social Media. After digesting last week's testimony and the conversations around it (visit www.fdasm.com for the latest courtesy of Fabio Gratton), Joel offers the following:
During my recent presentations at Digital Pharma and AdvaMed's Social Media Seminar, I argued that social media offers pharmaceutical and medical device brands a unique opportunity to engage with physicians. According to Mark Bard from Manhattan Research, 70% of physicians want pharmaceutical firms to engage them online and 60% of physicians either use or are interested in using physician social networks (just ask the docs on Ozmosis or Sermo). With thousands of physicians actively using social media every day to access and share medical information (see Rohit Bhargava's post on "How Doctors Are Using Social Media", one would expect pharmaceutical and medical device firms to salivate at the engagement possibilities.
Yet, both industries have been reluctant to engage doctors using social media under current FDA guidelines. Their reluctance has been disappointing to many but should not be surprising. Michele Sharp of Eli Lilly said it best at the FDA hearing:
To date, Lilly has avoided significant interaction with healthcare professionals and patients about our products in social media forums – largely because of a lack of clarity in understanding FDA’s expectations as to how we could participate and comply with FDA requirements.
This theme was reiterated throughout the hearings, and its absolutely critical that the FDA evaluate the impact of not providing guidance. Michele Sharp also nailed it when she called on the FDA to lead a series of public workshops that could, "collectively generate ideas, leverage the knowledge, expertise and experiences of the participants and work toward viable solutions, so that FDA can provide the detail and clarity to the pharmaceutical industry and others through Guidance or executive channels."
Lilly's recommendation is spot on, but in addition to immediately scheduling a series of public workshops…the FDA should appoint a Social Media Advisory Panel (a recommendation echoed by Zen Chu of Accelerated Medical Ventures). While holding the public hearings was a great step forward, the FDA needs to augment its social media expertise and it needs to do so quickly. Its clear from last week's testimony that the FDA has a lot of homework piling up and the best way we can accelerate their education is to demonstrate two very important points about social media use to the FDA.
1. Physicians and industry are already working together
2. Practical solutions exist to address the FDA's concerns
Read more »
« Collapse
